Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PRKDC | P78527 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 2/20 | 0.35 |
| ▸ | CES1 | P23141 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Urea SCHEMBL28877160 | 0.92 | ERN1 (0.43) | ERN1KDM4EALDH1A1PRKDCPTPN1 | |
| SCHEMBL29921177 | 0.82 | KDM4E (0.42) | ERN1KDM4EALDH1A1PRKDCPTPN1 | |
| SCHEMBL249018 | 0.82 | KDM4E (0.42) | ERN1KDM4EALDH1A1PRKDCPTPN1 | |
| SCHEMBL21676108 | 0.79 | AMY1A (0.37) | KDM4EALDH1A1PKMAMY1ALMNA | |
| SCHEMBL21662131 | 0.79 | RELA (0.49) | ERN1PTPN1RELA | |
| SCHEMBL4363014 | 0.78 | ERN1 (0.46) | ERN1KDM4EALDH1A1PTPN1LMNA | |
| SCHEMBL29957006 | 0.78 | ERN1 (0.46) | ERN1KDM4EALDH1A1PTPN1LMNA | |
| SCHEMBL4031066 | 0.77 | NFE2L2 (0.36) | ALDH1A1PKMAMY1ANFE2L2RELA | |
| SCHEMBL30132161 | 0.77 | AMY1A (0.38) | ALDH1A1PKMAMY1ALMNANFE2L2 | |
| SCHEMBL27563320 | 0.77 | AMY1A (0.38) | KDM4EALDH1A1PKMAMY1ANFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 799 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115536509-A | Synthesis method of 2-bromo-4-hydroxybenzaldehyde | 苏州金蚕新材料科技有限公司 | 2022-12-30 | — | — | CN | claimed |
| CN-114933607-A | Preparation method of 4-fluoro-2-hydroxymethyl phenylboronic acid and cliborole | 山东诺明康药物研究院有限公司 | 2022-08-23 | — | — | CN | claimed |
| CN-109485664-B | Preparation process of antifungal medicine tavaboroluo | 北京凯莱天成医药科技有限公司 | 2022-03-08 | — | — | CN | claimed |
| CN-110372722-B | Method for synthesizing sulfur-nitrogen-containing bis-heterocyclic compound | 河南师范大学 | 2020-08-11 | — | — | CN | claimed |
| CN-109485664-A | A kind of antifungal drug he cut down the preparation process of boron sieve | 北京凯莱天成医药科技有限公司 | 2019-03-19 | — | — | CN | claimed |
| CN-109312618-A | For hydraulic fracturing and for the method and composition of tracer water flooding | 光谱追踪服务有限责任公司 | 2019-02-05 | — | — | CN | claimed |
| US-10017684-B2 | Method and compositions for hydraulic fracturing and for tracing formation water | SPECTRUM TRACER SERVICES, LLC (US) | 2018-07-10 | — | — | US | claimed |
| CN-108033910-A | A kind of preparation method of 2- benzyls -3,4- dihydros -2H- isoquinoline-1-ketone derivatives | 上海应用技术大学 | 2018-05-15 | — | — | CN | claimed |
| US-20170306217-A1 | METHOD AND COMPOSITIONS FOR HYDRAULIC FRACTURING AND FOR TRACING FORMATION WATER | NCS Multistage, LLC | 2017-10-26 | — | — | US | claimed |
| EP-4161642-B1 | N-PHENYLAMINOCARBONYL PYRIDINO- , PYRIMIDINO AND BENZO-TROPANES AS MODULATORS OF GPR65 | PATHIOS THERAPEUTICS LTD (GB) | 2026-05-27 | — | — | EP | disclosed |
| EP-4720055-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | Arcus Biosciences, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12570602-B2 | Selective serotonin receptor modulators and methods of making and using the same | Park City Bio, LLC (US) | 2026-03-10 | — | — | US | disclosed |
| US-12564560-B1 | Selective serotonin receptor modulators and methods of making and using the same | Park City Bio, LLC (US) | 2026-03-03 | — | — | US | disclosed |
| US-20250382304-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-6313139-B1 | ADMINISTERING BENZYLAMINE DERIVATIVE FOR THERAPY OF PSYCHIATRIC DISORDER IN MAMMALS | AKZO NOBEL N. V. (NL) | 2001-11-06 | — | — | US | disclosed |
| EP-1020445-A1 | FUSED PYRIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
| US-6080773-A | USEFUL FOR TREATMENT OF DEPRESSION, ANXIETY OR PSYCHOSIS | AKZO NOBEL, N.V. (NL) | 2000-06-27 | — | — | US | disclosed |
| CN-1219169-A | Substituted benzylamines and their use for the treatment of depression | AKZO NOBEL NV (NL) | 1999-06-09 | — | — | CN | disclosed |
| EP-0898566-A1 | SUBSTITUTED BENZYLAMINES AND THEIR USE FOR THE TREATMENT OF DEPRESSION | Akzo Nobel N.V. (NL) | 1999-03-03 | — | — | EP | disclosed |
| WO-1997040027-A1 | SUBSTITUTED BENZYLAMINES AND THEIR USE FOR THE TREATMENT OF DEPRESSION | AKZO NOBEL N.V. (NL) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382304-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | CYP2C8, ABCB1, PAICS | ERN1 2620/4885KDM4E 1381/4885ALDH1A1 1313/4885 |
| US-12570602-B2 | Selective serotonin receptor modulators and methods of making and using the same | HTR1D, HTR1A, HTR4 | ERN1 3339/4885KDM4E 2555/4885ALDH1A1 3289/4885 |
| US-12564560-B1 | Selective serotonin receptor modulators and methods of making and using the same | HTR5A, HTR1A, HTR1D | ERN1 2573/4885KDM4E 2038/4885ALDH1A1 3950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.